Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed

EpigenomicsAhead of Print EditorialTumor mutation burden as a marker for molecularly matched therapy: more evidence neededXiang-Yu Meng & Qiu-Ji WuXiang-Yu Meng *Author for correspondence: E-mail Address: mengxy_whu@163.comhttps://orcid.org/0000-0001-5669-3502Health Science Center, Hubei Minzu University, Enshi, 445000, ChinaHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi, 445000, ChinaSearch for more papers by this author & Qiu-Ji Wu **Author for correspondence: E-mail Address: wuqiuji@126.comhttps://orcid.org/0000-0002-4655-3108Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumour Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, ChinaSearch for more papers by this authorPublished Online:15 Nov 2023https://doi.org/10.2217/epi-2023-0354AboutSectionsView ArticleView Full TextSupplemental MaterialPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: biomarkermolecularly matched therapyprognosistargeted therapytumor mutation burdenReferences1. Litchfield K, Reading JL, Puttick C et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184(3), 596–614; e514 (2021).Crossref, Medline, CAS, Google Scholar2. Mcgrail DJ, Pilie PG, Rashid NU et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32(5), 661–672 (2021).Crossref, Medline, CAS, Google Scholar3. De Bortoli T, Benary M, Horak P et al. Tumour mutational burden and survival with molecularly matched therapy. Eur. J. Cancer 190, 112925 (2023).Crossref, Medline, Google Scholar4. Offin M, Rizvi H, Tenet M et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res. 25(3), 1063–1069 (2019).Crossref, Medline, CAS, Google Scholar5. Lin C, Shi X, Zhao J et al. Tumor mutation burden correlates with efficacy of chemotherapy/targeted therapy in advanced non-small cell lung cancer. Front Oncol. 10, 480 (2020).Crossref, Medline, CAS, Google Scholar6. Smith AE, Ferraro E, Safonov A et al. HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat. Commun. 12(1), 6667 (2021).Crossref, Medline, CAS, Google Scholar7. Hyman DM, Piha-Paul SA, Won H et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554(7691), 189–194 (2018).Crossref, Medline, CAS, Google Scholar8. Taber A, Christensen E, Lamy P et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11(1), 4858 (2020).Crossref, Medline, CAS, Google Scholar9. Lengel HB, Mastrogiacomo B, Connolly JG et al. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell 41(5), 970–985; e973 (2023).Crossref, Medline, CAS, Google Scholar10. Tsang ES, Csizmok V, Williamson LM et al. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. NPJ Precis. Oncol. 7(1), 31 (2023).Crossref, Medline, CAS, Google Scholar11. Batalini F, Gulhan DC, Mao V et al. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clin. Cancer Res. 28(21), 4714–4723 (2022).Crossref, Medline, CAS, Google Scholar12. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 12(1), 31–46 (2022).Crossref, Medline, CAS, Google Scholar13. Neyret-Kahn H, Fontugne J, Meng XY et al. Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks. Oncogene 42(19), 1524–1542 (2023).Crossref, Medline, CAS, Google Scholar14. Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer 22(6), 323–339 (2022).Crossref, Medline, CAS, Google Scholar15. Zhou Q, Zhang XC, Chen ZH et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 29(24), 3316–3321 (2011).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Supplemental MaterialsMetrics Downloaded 0 times History Received 9 October 2023 Accepted 1 November 2023 Published online 15 November 2023 Information© 2023 Future Medicine LtdKeywordsbiomarkermolecularly matched therapyprognosistargeted therapytumor mutation burdenSupplementary dataTo view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2023-0354Author contributionsX-Y Meng, conceptualization, data curation, formal analysis, writing – original draft; Q-J Wu, data curation, writing – review editing.Financial disclosureX-Y Meng was supported by National Natural Science Foundation of China (82303057) and Natural Science Foundation of Hubei Province of China (2023AFB521). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download